Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties

Additionally, Sanofi has obtained exclusive rights to use Kiadis K-NK platform for two undisclosed pre-clinical programs.